ECU-NMO 301

Brief Description Of Study

A Phase 3 trial to evaluate the safety and efficacy of Eculizumab in the treatment of relapsing NMO. Target population must be 18 years and older, have a confirmed diagnosis of relapsing NMO, and have an EDSS score less than or equal to 7.

Clinical Study Identifier: 01892345

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: ECU-NMO 301
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.